account$429 million for the quarter from $435 a year ago as its Taxus device faced stiff competition from Abbott Laboratories' new Xience stent. U.S. sales of the devices reversed recent declines at $231 million compared with $224 million a year ago. Sales of...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Boston Scientific adjusted profit meets Street
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account